← All organizations
Highest phase reached
Phase 2
First clinical trial
Jan 1, 2011Last known activity
Nov 4, 2025
Timeline
2000s
- Jun 1, 2007
Fate Therapeutics— Founded
Drugs by trial phase (40 distinct, 21 trials)
Phase 2 (3 own, 0 via acquisition)
Indications
Studied for
- Carcinoma
- Carcinoma, Merkel Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Colorectal Neoplasms
- Graft vs Host Disease
- Head and Neck Neoplasms
- Hodgkin Disease
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Melanoma
- Metabolic Diseases
- Microsatellite Instability
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasms
- Neoplasms, Plasma Cell
- Pancreatic Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
Recent trials (39)
- NCT07216105OfficialPhase 1Nov 4, 2025
- NCT07216105Lead sponsorPhase 1Nov 4, 2025
- NCT06308978Lead sponsorPhase 1Mar 28, 2024
- NCT06241456OfficialPhase 1Jan 5, 2024
- NCT06241456Lead sponsorPhase 1Jan 5, 2024
- NCT05950334Lead sponsorPhase 1Nov 1, 2023
- NCT05950334Study directorPhase 1Nov 1, 2023
- NCT05934097Study directorPhase 1Dec 31, 2022
- NCT05934097Lead sponsorPhase 1Dec 31, 2022
- NCT05395052Study directorPhase 1May 31, 2022
- NCT05395052Lead sponsorPhase 1May 31, 2022
- NCT05182073Study directorPhase 1Nov 24, 2021
- NCT05182073Lead sponsorPhase 1Nov 24, 2021
- NCT05069935Lead sponsorPhase 1Oct 15, 2021
- NCT05069935Study directorPhase 1Oct 15, 2021
Details
- Founded
- La Jolla, CA, US Jun 1, 2007
- Last known activity
- Nov 4, 2025